Lupin Limited has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), desvenlafaxine extended-release tablets, 25 mg to market a generic equivalent of Pristiq extended-release tablets, 25 mg of PF PRISM C.V. The product will be manufactured at Lupin
